Xvivo Perfusion AB 

SEK263
6
+SEK10.4+4.12% Friday 15:22

統計

當日最高
267
當日最低
260
52週高點
343.52
52週低點
205.5
成交量
13,622
平均成交量
-
市值
0
本益比
10.35
股息殖利率
-
股息
-

即將到來

財報

24Apr預期
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
下一步
-0.04
0.06
0.17
0.27
預期EPS
0.099414
實際EPS
不適用

財務

1.98%利潤率
有盈利
2020
2021
2022
2023
2024
2025
2.21B營收
43.84M淨利

其他人也在關注

此清單是根據在 Stock Events 上追蹤 0RKL.LSE 的使用者自選建立的。這不是投資建議。

競爭對手

此清單為基於近期市場事件的分析。並非投資建議。

關於

Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment. In addition, the company offers Kidney Assist that provides clinicians with a choice of perfusion protocols from hypothermic to normothermic perfusion; and Gisto, an integrated system for organ transportation. It operates in Sweden; The Netherlands; The United States; Italy; North and South America; Asia/Pacific and Oceania; and internationally. Xvivo Perfusion AB (publ) was incorporated in 1998 and is headquartered in Mölndal, Sweden.
Show more...
執行長
Mr. Christoffer Rosenblad
員工
198
國家
GB
ISIN
SE0004840718

上市

0 Comments

分享你的想法

FAQ

Xvivo Perfusion AB 今天的股價是多少?
0RKL.LSE 目前價格為 SEK263 SEK,過去 24 小時上漲了 +4.12%。在圖表上更密切關注 Xvivo Perfusion AB 股價表現。
Xvivo Perfusion AB 的股票代號是什麼?
根據交易所不同,股票代號可能會有所差異。例如,在 交易所,Xvivo Perfusion AB 的股票以代號 0RKL.LSE 進行交易。
Xvivo Perfusion AB 的股價在上漲嗎?
0RKL.LSE 股票較上週上漲 +9.58%,本月上漲 +43.79%,但過去一年 Xvivo Perfusion AB 下跌 -2.45%。
Xvivo Perfusion AB 下一次財報日期是什麼時候?
Xvivo Perfusion AB 將於 April 24, 2026 公布下一次財報。
Xvivo Perfusion AB 上一季度的財報如何?
0RKL.LSE 上一季度的財報為每股 0.99 SEK,預估為 0.65 SEK,帶來 +52.77% 的驚喜。下一季度的預估財報為每股 不適用 SEK。
Xvivo Perfusion AB 去年的營收是多少?
Xvivo Perfusion AB 去年的營收為 2.21BSEK。
Xvivo Perfusion AB 去年的淨利是多少?
0RKL.LSE 去年的淨收益為 43.84MSEK。
Xvivo Perfusion AB 有多少名員工?
截至 April 11, 2026,公司共有 198 名員工。
Xvivo Perfusion AB 位於哪個產業?
Xvivo Perfusion AB從事於Industrials產業。
Xvivo Perfusion AB 何時完成拆股?
Xvivo Perfusion AB 最近沒有進行任何拆股。
Xvivo Perfusion AB 的總部在哪裡?
Xvivo Perfusion AB 的總部位於 GB 的 Mölndal。